D89.F Stock Analysis
D8
Uncovered
Destiny Pharma PLC is uncovered by Eyestock quantitative analysis.
Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex and currently employs 18 full-time employees. The company went IPO on 2017-09-04. The firm is engaged in the discovery, development, and commercialization of medicines with a focus on infection prevention. Its pipeline includes microbiome-based biotherapeutics and XF drug clinical assets, which includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. Its lead drug candidate, NTCD-M3, is in Phase III ready treatment for the prevention of Clostridioides difficile infection (CDI) recurrence, which causes hospital acquired infection in the United States. Its second lead candidate, XF-73 nasal gel, which has completed Phase IIb clinical trial targeting the prevention of post-surgical staphylococcal hospital infections, including methicillin-resistant Staphylococcus aureus (MRSA). The firm is also co-developing SPOR-COV, a biotherapeutic product for the prevention of COVID-19 and influenza, an in-house XF-73 dermal program, targeting wound and skin infections, and other XF research projects.